

Naxitamab

Cat. No.:	HY-P99206
CAS No.:	1879925-92-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers ^[1] .	
In Vitro	Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC ₅₀ value of 5.1 µg/mL ^[1] . Naxitamab (0.1-1 µg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female athymic nude mice with LAN-1 xenografts ^[1]
	Dosage:	100 mg/kg
	Administration:	Intravenous injection; twice a week, for 4 weeks
	Result:	Inhibited tumor growth and prolonged the survival time.

REFERENCES

[1]. Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. *Oncoimmunology*. 2012 Jul 1;1(4):477-486.

[2]. Markham A. Naxitamab: First Approval. *Drugs*. 2021 Feb;81(2):291-296.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA